Adial Pharma – Phase 3 Drug Candidate for Alcohol Abuse Disorder (AUD)

Bill Stilley, is CEO and President of Adial Pharma, a company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). He discusses the company’s lead product AD04, a genetically targeted therapeutic for the treatment of AUD and the promising results from the phase 2b clinical trial in reducing frequency and quantity of drinking. AD04 is now in Phase 3 and has the potential to be an effective and safe treatment option for AUD that does not require abstinence as part of the treatment and does not have the negative side effects of the current drugs on the market. 

William B. Stilley has served as our Chief Executive Officer since co-founding the company in December 2010. Prior to joining Adial Pharmaceuticals, he was the Vice President, Business Development & Strategic Projects at Clinical Data, Inc. (NASDQ CLDA), where he worked on licensing and M&A transactions and was involved in management of Phase 3 clinical trials, production of Viibryd ®  for initial commercial launch of the product, and sourcing drug product and drug substance for the Phase 3 clinical trials of the Company’s vasodilator drug for myocardial stress imaging. He has advised both public and private companies on financing and M&A transactions, and has been the COO and CFO of a number of private companies. Before entering the business community, Mr. Stilley served as Captain in the U.S. Marine Corps.  Mr. Stilley has an MBA with honors from the Darden School of Business and a B.S. in Commerce/Marketing from the McIntire School of Commerce at the University of Virginia. He has guest lectured at the Darden School of Business in two courses on the management of life science companies, and serves on the Advisory Board of Virginia BIO, the statewide biotechnology organization, and previously served on Virginia BIO’s board of directors.